Biofrontera Inc. (BFRI) Stock Score, Valuation & Financial Research
Biofrontera Inc. is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for BFRI
Biofrontera Inc. currently has a Wall Street Score of 22/100. The stored market price is $1.36. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Biofrontera Inc. does
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRI financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $1.36
- Market capitalization:
- $17.4M
- Revenue:
- $46.2M
- Net income:
- $-6.4M
- Free cash flow:
- $-13.4M
- Cash:
- $4.7M
- Total debt:
- $7.5M
- EPS:
- -0.60
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 39/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-13.4M, showing cash burn in the current stored period.
- The balance sheet shows $4.7M of cash versus $7.5M of total debt, so leverage deserves attention.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BFRI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.